No Data Available
AFT Pharmaceuticals Limited (AFP)
is a publicly listed company on the Australian Securities Exchange (ASX).
About AFT Pharmaceuticals
They started small. But They dreamed big.
Back in 1997, husband and wife team Hartley and Marree Atkinson hit the road selling products direct to pharmacies. AFT Pharmaceuticals was formed with a big dream in mind.
In Australasia, their product line now extends to over 130 prescription and non-prescription products. They have offices in Singapore, Kuala Lumpur, Sydney and Auckland (their HQ). They export or license their products to over 109 countries. Plus their Orphan Drugs Foundation provides access to lower cost pharmaceuticals for people with rare diseases within South East Asia and the Pacific.
This success has been built on research and development. R&D is more than corporate speak for them. It’s at the heart of what they do, whether it’s developing new products, or improving existing existing ones. It’s also due to the fact that they are close to the market. Because they sell their own products they are constantly looking for changes in health needs and how they can fill gaps that emerge.
Their ideas, their researchers, their specialist drug development programmes, and the international experts they partner with have allowed them to grow year on year. It’s how they’ve managed to forge a place on the world stage in the extremely competitive pharmaceutical industry.
They’re proud of their past achievements. They’re ambitious for the future.
Vision & Mission
What’s their company vision?
It’s pretty simple really, their vision is to develop innovative products that help people.
They do this by looking at healthcare needs, understanding how those needs are changing, and how they can provide treatment options that work.
Their success as a company has been built on seeing opportunities in areas that others have missed.
Their guiding principle is to do things better than they've have been done before. Whether it’s developing products with multiple-benefits, creating drug delivery devices that produce less discomfort for patients, or getting lower-cost drugs to people with rare diseases, they’re always focused on improving the status quo.
This has allowed them to grow as a company, and crucially, to help meet the health needs of people in Australasia and in more recent years, around the globe.
Orphan drugs are treatments for people with rare medical conditions.
People with rare medical conditions often find that treatments are either unaffordable or simply do no exist.
Typically this is because drug development is costly, and companies can find it difficult to recoup their investment when the number of people suffering from a particular condition are relatively few.
These people effectively become treatment ‘orphans’ - hence the term. Globally, nearly 7,000 rare diseases have been identified.1 While ‘rare’ implies that few people suffer from a condition, when extrapolated out across whole populations, the number of people with rare conditions can be very large. For instance, it’s estimated that 30 million people have a rare condition in the US,2 and a further 30 million in Europe.
Nevertheless, some pharmaceutical companies do develop, and make available, treatments for people with rare conditions. These are 'orphan drugs' or ‘orphan treatments’. AFT Pharmaceuticals is one such company.
To encourage companies to develop treatments for rare conditions, the regulatory requirements for developing and licensing treatments can be lessened by a regulator. For example, clinical testing studies may be permitted to use smaller patient groups. Tax incentives or research grants can be offered and patent protections increased. These incentives exist in the US and Europe legislation, but do not in New Zealand.
AFT Pharmaceuticals Limited
113 Wicks Road
North Ryde, NSW
+61 2 9420 0420
Fax: +61 800 041 026
The General Overview, Services, Products and Projects information for this profile was last edited on 17 Jun 2016.